Table 1.

Base-case estimates and ranges

Result or transition	Estimate	Range	References
TITAN
Cohort age at start, mean, y	42	19-72	11
Probability of death, SOC arm	0.054		11
Probability of death, caplacizumab arm	0		11
Probability of total recurrence SOC arm	0.324		11
Probability of total recurrence, caplacizumab arm	0.314		11
Probability of total relapse at 5 y	0.4	0.19-0.4	3, 8, 22
Discount rate	0.03	0.015-0.06	23
HERCULES
Cohort age at start, mean, y	46	18-79	12
Probability of death, SOC arm	0.041		12
Probability of death caplacizumab arm	0.014		12
Probability of total recurrence, SOC arm	0.384		12
Probability of total recurrence, caplacizumab arm	0.125		12
Discount rate	0.03	0.015-0.06	23